...
nlsp-img

NLS Pharmaceutics AG, Common Stock

NLSP

NAQ

$2.01

+$0.03

(1.52%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$4.74M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.59M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.52
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.75 L
$24.34 H
$2.01

About NLS Pharmaceutics AG, Common Stock

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameNLSPSectorS&P500
1-Week Return-25.83%-1.8%-0.77%
1-Month Return-49.37%-3.48%0.71%
3-Month Return-61.08%-7.2%8.81%
6-Month Return-61.67%-1.54%12.32%
1-Year Return-88.45%8.39%30.57%
3-Year Return-96.1%6.07%29.21%
5-Year Return-98.26%44.07%91.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue--10.05K11.41K11.41K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":88.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit--(10.05K)(11.41K)(11.41K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1005000,"profit":false},{"date":"2022-12-31","value":-1140800,"profit":false},{"date":"2023-12-31","value":-1140800,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses4.20M2.30M11.85M15.47M11.81M[{"date":"2019-12-31","value":27.13,"profit":true},{"date":"2020-12-31","value":14.86,"profit":true},{"date":"2021-12-31","value":76.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.32,"profit":true}]
Operating Income(4.20M)(2.30M)(11.86M)(15.48M)(11.81M)[{"date":"2019-12-31","value":-419704000,"profit":false},{"date":"2020-12-31","value":-229937000,"profit":false},{"date":"2021-12-31","value":-1186062000,"profit":false},{"date":"2022-12-31","value":-1548236000,"profit":false},{"date":"2023-12-31","value":-1180706300,"profit":false}]
Total Non-Operating Income/Expense(2.07M)(795.76K)(153.59K)(1.11M)(510.12K)[{"date":"2019-12-31","value":-206981600,"profit":false},{"date":"2020-12-31","value":-79576500,"profit":false},{"date":"2021-12-31","value":-15359100,"profit":false},{"date":"2022-12-31","value":-111418200,"profit":false},{"date":"2023-12-31","value":-51011900,"profit":false}]
Pre-Tax Income(5.45M)(2.86M)(11.95M)(16.50M)(12.17M)[{"date":"2019-12-31","value":-544714500,"profit":false},{"date":"2020-12-31","value":-286143500,"profit":false},{"date":"2021-12-31","value":-1194607800,"profit":false},{"date":"2022-12-31","value":-1649568000,"profit":false},{"date":"2023-12-31","value":-1217202900,"profit":false}]
Income Taxes(4.20K)(2.30K)(226.51K)2.002.00[{"date":"2019-12-31","value":-209852,"profit":false},{"date":"2020-12-31","value":-114968.5,"profit":false},{"date":"2021-12-31","value":-11325400,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(5.44M)(2.86M)(11.72M)(16.50M)(12.17M)[{"date":"2019-12-31","value":-544294796,"profit":false},{"date":"2020-12-31","value":-285913563,"profit":false},{"date":"2021-12-31","value":-1171957000,"profit":false},{"date":"2022-12-31","value":-1649568200,"profit":false},{"date":"2023-12-31","value":-1217203100,"profit":false}]
Income From Continuous Operations(5.45M)(2.86M)(11.95M)(16.50M)(12.17M)[{"date":"2019-12-31","value":-544714600,"profit":false},{"date":"2020-12-31","value":-286143500,"profit":false},{"date":"2021-12-31","value":-1194607800,"profit":false},{"date":"2022-12-31","value":-1649568000,"profit":false},{"date":"2023-12-31","value":-1217202800,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(5.45M)(2.86M)(11.95M)(16.50M)(12.17M)[{"date":"2019-12-31","value":-544714500,"profit":false},{"date":"2020-12-31","value":-286143500,"profit":false},{"date":"2021-12-31","value":-1194607800,"profit":false},{"date":"2022-12-31","value":-1649568000,"profit":false},{"date":"2023-12-31","value":-1217202900,"profit":false}]
EPS (Diluted)(0.75)(0.92)(1.66)--[{"date":"2019-12-31","value":-74.61,"profit":false},{"date":"2020-12-31","value":-92.34,"profit":false},{"date":"2021-12-31","value":-166,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

NLSP
Cash Ratio 0.07
Current Ratio 0.15
Quick Ratio 0.12

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NLSP
ROA (LTM) -227.76%
ROE (LTM) -862.92%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NLSP
Debt Ratio Lower is generally better. Negative is bad. 8.77
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -7.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NLSP
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 4.84
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is NLS Pharmaceutics AG share price today?

NLS Pharmaceutics AG (NLSP) share price today is $2.01

Can Indians buy NLS Pharmaceutics AG shares?

Yes, Indians can buy shares of NLS Pharmaceutics AG (NLSP) on Vested. To buy NLS Pharmaceutics AG from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NLSP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of NLS Pharmaceutics AG be purchased?

Yes, you can purchase fractional shares of NLS Pharmaceutics AG (NLSP) via the Vested app. You can start investing in NLS Pharmaceutics AG (NLSP) with a minimum investment of $1.

How to invest in NLS Pharmaceutics AG shares from India?

You can invest in shares of NLS Pharmaceutics AG (NLSP) via Vested in three simple steps:

  • Click on Sign Up or Invest in NLSP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in NLS Pharmaceutics AG shares
What is NLS Pharmaceutics AG 52-week high and low stock price?

The 52-week high price of NLS Pharmaceutics AG (NLSP) is $24.34. The 52-week low price of NLS Pharmaceutics AG (NLSP) is $1.75.

What is NLS Pharmaceutics AG price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of NLS Pharmaceutics AG (NLSP) is

What is NLS Pharmaceutics AG price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of NLS Pharmaceutics AG (NLSP) is 4.84

What is NLS Pharmaceutics AG dividend yield?

The dividend yield of NLS Pharmaceutics AG (NLSP) is 0.00%

What is the Market Cap of NLS Pharmaceutics AG?

The market capitalization of NLS Pharmaceutics AG (NLSP) is $4.74M

What is NLS Pharmaceutics AG’s stock symbol?

The stock symbol (or ticker) of NLS Pharmaceutics AG is NLSP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top